Research suggests that 50% to 60% of cases labeled HER2-negative may actually be HER2-low, and 10% to 20% may be HER2-ultralow.
Learn why that matters and what it could mean for your treatment options here: https://bit.ly/3OTwUV2
#breastcancer #HER2negative #breastcancersurvivors
In a phase 3 trial, #culmerciclib plus #fulvestrant improved PFS and response rates versus fulvestrant alone in pretreated #HRPositive, #HER2Negative advanced #BreastCancer, supporting dual CDK2/4/6 targeting to overcome resistance.
#OpenAccess in #STTT: doi.org/10.1038/s413...
Lynparza just showed long-term survival benefits for breast cancer patients after 6 years of follow-up. A huge step forward in treatment!
#breastcancer #CancerResearch #CancerTreatment #Lynparza #BRCA #HER2Negative #HopeForCancer #MedicalInnovation #PharmaNews #CancerAwareness #BreastCancer
